Press Release Summary:
The SPiN Access Catheter™ offers accurate 3D map for navigation, respiratory gating and compatibility with Always-On Tip Tracked® sampling instruments. The unit comes with a tip tracked instruments and ability to transition to a navigated TTNA.
Original Press Release:
Veran Launches New Navigated Catheter to Help Physicians Diagnose and Guide Treatment of Smaller, Early-stage Lung Cancer Lesions
Veran Medical continues its mission to help physicians diagnose and treat lung cancer earlier with the launch of a new navigated catheter and two new navigation software applications that are designed to help diagnose and guide treatment of small suspicious nodules likely to be early stage lung cancer. Veran is launching this new navigated catheter and new software applications at the CHEST Annual Meeting in San Antonio, TX.
SAN ANTONIO (PRWEB) OCTOBER 05, 2018 - Veran Medical is officially launching their new SPiN Access Catheter™, an extended working channel navigated by an Always-On Tip Tracked® guidewire. The SPiN Access Catheter™ provides lung specialists a catheter-based approach they are familiar with, but with the added advantages of a more accurate 3D map for navigation, respiratory gating, and compatibility with Always-On Tip Tracked® sampling instruments. This new catheter enables more accurate 3D navigation without the need for intraprocedural fluoroscopy during sampling.
The first ever procedures with the new SPiN Access Catheter™ were completed on October 4th by Dr. Sandeep Bansal, an Interventional Pulmonologist at Penn Highlands Healthcare in Dubois, PA. “The SPiN Access Catheter™ is a game changer as it provides me with an extended working channel approach but with Veran’s added benefits of more accurate navigation, the ability to track respiration, tip tracked sampling instruments, and the ability to transition to a navigated TTNA, when needed,” said Dr. Sandeep Bansal. “This will help us to diagnose lung cancer earlier, and will therefore ultimately help save lives.”
“The expanding adoption of lung cancer screening has given us a real opportunity to catch cancer earlier and save lives, but only if we can help physicians reach the smallest nodules,” said Veran Medical CEO Jason Pesterfield. “Our new software applications and SPiN Access Catheter™ provide additional flexibility to help physicians reach and guide treatment for early stage cancer when patients have the best prognosis.”
Veran’s next generation SPiN Thoracic Navigation System™ offers an industry leading precision thoracic guidance platform that allows lung specialists to seamlessly transition between a navigated endobronchial approach and a navigated transthoracic approach utilizing SPiN Perc™, to help physicians diagnose lung cancer earlier. A published clinical study utilizing a multi-modality approach, including Veran’s SPiN System™ and SPiN Perc™, have demonstrated a 92% diagnostic yield.
Lung Cancer remains the number one cancer killer worldwide. 94 million current or former smokers remain at elevated risk in the U.S. alone. More than 8 million people in the U.S. currently meet the criteria for lung cancer screening. When suspicious lesions are discovered, patients need answers. But mounting clinical data suggests that a large percentage of the hundreds of thousands of bronchoscopies performed every year on suspected lung cancer patients are non-diagnostic—delaying potential lifesaving therapy.
About Veran Medical Technologies
Veran is a privately held medical device company headquartered in St. Louis, MO. The company’s mission is to empower physicians to diagnose cancer earlier and to enable precision therapy to save lives. In the United States, lung cancer kills more people each year than breast, prostate, pancreatic and colon cancers combined.
Veran has developed and commercialized an FDA cleared, next generation electromagnetic thoracic navigation platform called the SPiN Thoracic Navigation System™. Veran’s breakthrough technology has been adopted by leading cancer centers throughout the United States. Veran provides physicians with a full line of bronchoscopic brushes, needles, forceps and steerable catheters with tiny electromagnetic sensors embedded in the tips for precise navigation. The combination of these proprietary Always-On Tip Tracked® instruments and Veran’s exclusive patient respiratory gating technology enables physicians to accurately access lung nodules by accounting for nodule movement during patient breathing, a common challenge for lung specialists.
Another challenge lung specialists face is that approximately 40% of lung nodules lie outside of an airway, making them very difficult to reach endobronchially, and traditionally requiring an additional procedure. Veran’s SPiN Thoracic Navigation System™ is the first and only FDA cleared technology that enables Pulmonologists or Thoracic Surgeons to safely and accurately access lung nodules outside of an airway using SPiN Perc™, a navigated transthoracic needle. With SPiN Perc™, Veran combines endobronchial navigation with percutaneous navigation, allowing physicians to access all lung nodules in a single procedure, regardless of nodule size or location. This eliminates the cost and risk of unnecessary procedures and empowers physicians to provide a same day diagnosis for their patients. The early diagnosis and treatment of lung cancer has been proven to save lives.